Valuation: Amgen Inc.

Market Cap 235B 354,838B 209B 195B 177B 333B 22,225B 339B 2,338B 915B 11,596B 881B 862B 37,106B P/E 2026 *
27.6x
P/E 2027 * 24.6x
Enterprise Value 276B 417,377B 246B 229B 208B 392B 26,142B 399B 2,750B 1,076B 13,640B 1,036B 1,014B 43,646B EV / Sales 2026 *
7.08x
EV / Sales 2027 * 6.68x
Free-Float
99.77%
Yield 2026 *
2.32%
Yield 2027 * 2.46%
1 day+2.05%
1 week+6.90%
Current month+3.18%
1 month+17.30%
3 months+25.15%
6 months+39.06%
Current year+40.31%
1 week 22,120
Extreme 22120
23,820
1 month 20,000
Extreme 20000
23,820
Current year 15,920
Extreme 15920
23,820
1 year 12,320
Extreme 12320
23,820
3 years 7,000
Extreme 7000
23,820
5 years 1,312
Extreme 1312
23,820
10 years 273.67
Extreme 273.666666
23,820
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Chief Tech/Sci/R&D Officer 57 31/05/2023
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%+6.90% - - 235B
+3.55%+7.01%+51.42%+105.45% 1,116B
-0.25%-1.25%+32.49%+61.48% 610B
+0.59%+4.03%+25.28%+91.54% 501B
-1.48%+1.97%+72.62%+39.59% 358B
+2.37%+7.66%+33.65%+48.87% 366B
+2.64%+6.95%+21.01%+43.85% 288B
+3.24%+6.78%+0.43%+15.71% 261B
+1.86%+6.53%+45.98%+52.77% 235B
+2.49%+6.98%+33.03%+102.67% 195B
Average +1.71%+5.27%+35.10%+62.44% 436.64B
Weighted average by Cap. +1.79%+4.93%+38.57%+71.82%

Financials

2026 *2027 *
Net sales 38.97B 58,938B 34.79B 32.33B 29.41B 55.33B 3,691B 56.33B 388B 152B 1,926B 146B 143B 6,163B 40.4B 61,085B 36.06B 33.51B 30.48B 57.35B 3,826B 58.38B 403B 158B 1,996B 152B 148B 6,388B
Net income 8.54B 12,914B 7.62B 7.08B 6.44B 12.12B 809B 12.34B 85.1B 33.3B 422B 32.05B 31.37B 1,350B 9.43B 14,254B 8.41B 7.82B 7.11B 13.38B 893B 13.62B 93.93B 36.75B 466B 35.37B 34.62B 1,491B
Net Debt 41.36B 62,539B 36.91B 34.31B 31.21B 58.71B 3,917B 59.77B 412B 161B 2,044B 155B 152B 6,540B 35.3B 53,376B 31.51B 29.28B 26.64B 50.11B 3,343B 51.01B 352B 138B 1,744B 132B 130B 5,582B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
15/10/26 ARS 23,390.00 +2.05% 2,764
14/10/26 ARS 22,920.00 +3.62% 8,911
13/10/26 ARS 22,120.00 -0.72% 972
09/10/26 ARS 22,280.00 +1.83% 401
08/10/26 ARS 21,880.00 -1.40% 741
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
434.03USD
Average target price
394.98USD
Spread / Average Target
-9.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.